Expat arrested for immoral act at a massage center in Jazan    Saudi Transplant Congress discusses scientific advancements and innovations on organ donation and transplantation    Saudi non-oil exports jump 13.1%, with volume of trade exceeding SR2 trillion, in 2024    Mawani and Alissa Universal Motors sign agreement worth SR300 million to establish Logistics Zone at King Abdulaziz Port in Dammam    4 Chinese nationals arrested in Makkah for promoting fake Hajj campaigns    Saudi market shows resilience in Q1 2025 despite global volatility: Report    Saudi Arabia urges India and Pakistan to de-escalate tensions    Trump congratulates Canada's Carney as they agree to meet in 'near future'    Sánchez vows to uncover reasons behind massive Iberian power outage    Guterres warns two-state solution is 'near a point of no return'    Al Ahli stun Al Hilal to reach AFC Champions League Elite final    Al-Khereiji at BRICS: Saudi Arabia a reliable and neutral partner in endeavors for de-escalating tensions    Health Ministry launches World Health Survey 2025 Survey to collect accurate health status database of Saudi population    SR200,000 reward for each player of the Saudi club winning AFC Champions League title    Housing minister expects moderate real estate prices in Riyadh    William and Kate celebrate anniversary on Isle of Mull    HONOR KSA expands its presence with new flagship Experience Store in Riyadh HONOR's first flagship store in KSA provides visitors with a premium experience, exciting offers and free services    Rock & Roll Hall of Fame picks Outkast but not Oasis    Duran leads Al Nassr past Yokohama Marinos into AFC Champions League Elite semi-finals    Al Ahli cruise past Buriram into AFC Champions League Elite semi-finals    Pakistani star's Bollywood return excites fans and riles far right    Veteran Bollywood actor Manoj Kumar dies at 87    Bollywood actress vindicated over boyfriend's death after media hounding    Grand Mufti rules against posting prayers and preaching in mosques on social media    Exotic Taif Roses Simulation Performed at Taif Rose Festival    Asian shares mixed Tuesday    Weather Forecast for Tuesday    Saudi Tourism Authority Participates in Arabian Travel Market Exhibition in Dubai    Minister of Industry Announces 50 Investment Opportunities Worth over SAR 96 Billion in Machinery, Equipment Sector    HRH Crown Prince Offers Condolences to Crown Prince of Kuwait on Death of Sheikh Fawaz Salman Abdullah Al-Ali Al-Malek Al-Sabah    HRH Crown Prince Congratulates Santiago Peña on Winning Presidential Election in Paraguay    SDAIA Launches 1st Phase of 'Elevate Program' to Train 1,000 Women on Data, AI    41 Saudi Citizens and 171 Others from Brotherly and Friendly Countries Arrive in Saudi Arabia from Sudan    Saudi Arabia Hosts 1st Meeting of Arab Authorities Controlling Medicines    General Directorate of Narcotics Control Foils Attempt to Smuggle over 5 Million Amphetamine Pills    NAVI Javelins Crowned as Champions of Women's Counter-Strike: Global Offensive (CS:GO) Competitions    Saudi Karate Team Wins Four Medals in World Youth League Championship    Third Edition of FIFA Forward Program Kicks off in Riyadh    Evacuated from Sudan, 187 Nationals from Several Countries Arrive in Jeddah    SPA Documents Thajjud Prayer at Prophet's Mosque in Madinah    SFDA Recommends to Test Blood Sugar at Home Two or Three Hours after Meals    SFDA Offers Various Recommendations for Safe Food Frying    SFDA Provides Five Tips for Using Home Blood Pressure Monitor    SFDA: Instant Soup Contains Large Amounts of Salt    Mawani: New shipping service to connect Jubail Commercial Port to 11 global ports    Custodian of the Two Holy Mosques Delivers Speech to Pilgrims, Citizens, Residents and Muslims around the World    Sheikh Al-Issa in Arafah's Sermon: Allaah Blessed You by Making It Easy for You to Carry out This Obligation. Thus, Ensure Following the Guidance of Your Prophet    Custodian of the Two Holy Mosques addresses citizens and all Muslims on the occasion of the Holy month of Ramadan    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



Saudi FDA gives the green light to Pfizer's new breakthrough drug
Published in The Saudi Gazette on 29 - 01 - 2017

Breast cancer patients in advanced stage now find hope as the Saudi FDA approved palbociclib in combination with letrozole for the treatment of postmenopausal women with oestrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) metastatic (advanced) breast cancer (mBC) as initial endocrine-based therapy for their disease.1
Last year, palbociclib received an accelerated approval from the US Food and Drug Administration (FDA) and was the first cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor approved by the governing body.
Professor Samia Al-Amoudi, CEO, Sheikh Mohammed Hussein Al-Amoudi Center of Excellence in Breast Cancer, said: "Breast cancer is the most common cause of cancer death in women in the Middle East and North Africa and is responsible for 21% of female cancer deaths".2
In Saudi Arabia breast cancer is the most common cancer among female and constitute 29.1% of all women's cancer according to cancer registry in 2013. The coming burden of cancer is estimated to show increase in incidence and mortality by 350% and 160% respectively by 2050, according to a study by Ezzeldin M. Ibrahim, Chief Medical Officer and Chairman of Research Center in International Medical Center Hospital in Jeddah. This is alarming and shows that proper steps need to be taken by all involved in early detection, prevention and management.
Palbociclib inhibits the enzymes called cyclin-dependent kinases (CDKs) 4 and 6, which promote the growth of cancer cells. It is indicated for postmenopausal women with ER+/HER2- metastatic breast cancer who have not yet received and endocrine-based therapy. It is to be used in combination with letrozole, a product used to treat certain kinds of breast cancer in postmenopausal women.1
In the US, a clinical study was held wherein palbociclib was tested in 165 postmenopausal women with ER+/HER2- with locally advanced or metastatic breast cancer who did not have previous systemic treatment for the advanced disease. The study participants were randomly assigned to receive palbociclib combined with letrozole alone. The results showed that participants who received palbociclib and letrozole lived about 20.2 months without mBC progressing (known as progression-free survival or PFS), a substantial improvement as against the 10.2 months of PFS observed in women who were only on letrozole.3
The recommended dose of palbociclib is 125 mg taken orally once for 21 days followed by 7 days of treatment in 28-day cycles. Palbociclib should be taken with food and in combination with letrozole 2.5 mg once daily continuously.1
Patients are encouraged to take their doses at approximately the same time each day and not to combine with other medications apart from letrozole.
PIH LEAD Alaa Gamal said: "Our strength in research and innovation has just translated novel science into meaningful medicine. There is hope as efforts to develop newer and more effective treatments continue to help patients have a quality of life. Thanks to our strong partnerships with researchers, we now have a first-line treatment option which has shown its benefits in combination with letrozole to help achieve a longer progression-free survival for postmenopausal women with ER+/HER2- metastatic breast cancer." — SG


Clic here to read the story from its source.